

RESEARCH ARTICLE

Open Access

# The 4q27 locus and prostate cancer risk

Elizabeth A Tindall<sup>1,2</sup>, Hoa N Hoang<sup>3</sup>, Melissa C Southey<sup>4</sup>, Dallas R English<sup>3,5</sup>, John L Hopper<sup>5</sup>, Graham G Giles<sup>3,5</sup>, Gianluca Severi<sup>3,5</sup>, Vanessa M Hayes<sup>1,2\*</sup>

## Abstract

**Background:** Chronic inflammation is considered to be implicated in the development of prostate cancer. In this study we are the first to investigate a potential association between variants in an autoimmune related region on chromosome 4q27 and prostate cancer risk. This region harbors two cytokine genes *IL-2* and the recently described *IL-21*.

**Methods:** We genotyped six variants previously associated with autoimmune disease (namely rs13151961, rs13119723, rs17388568, rs3136534, rs6822844 and rs6840978) and one functional *IL-2* promoter variant (rs2069762) for possible association with prostate cancer risk using the Australian Risk Factors for Prostate Cancer case-control Study.

**Results:** Overall, our results do not support an association between the seven variants at position 4q27 and prostate cancer risk. Per allele odds ratios (ORs) were not significantly different from 1 (all P-values = 0.06). However, we found suggestive evidence for a significant association between the presence of the rs13119723 variant (located in a protein of unknown function) and men with a family history of prostate cancer in first-degree relatives (P-value for interaction 0.02). The per allele OR associated with this variant was significantly higher than 1 (2.37; 95% C.I. = 1.01-5.57).

**Conclusions:** We suggest that genetic variation within the chromosome 4q27 locus might be associated with prostate cancer susceptibility in men with a family history of the disease. Furthermore, our study alludes to a potential role of unknown protein KIAA1109 in conferring this risk.

## Background

Prostate cancer is the most common cancer affecting men in Western society and is the second highest contributor to cancer-related deaths world-wide [1]. Despite such vast prevalence little is known about the etiology of prostate cancer. To date, there are three well-defined risk factors, which include increased age, ethnicity and a family history of the disease [2]; evidence for the latter supporting a genetic contribution to prostate cancer risk. More recently, inflammation has been implicated in prostate cancer pathogenesis [3].


Different forms of prostate specific inflammation, including chronic prostatitis and proliferative inflammatory atrophy (PIA) have been frequently associated with the development of prostate cancer [4,5]. As an understanding of the role of inflammation in the etiology of prostate cancer begins to emerge, an imbalance in

cytokine production is thought to contribute to chronic inflammation and a failed tumor immune response. Suggestions that these specific inflammatory mediated conditions may in fact be pre-cursor lesions to prostate cancer development have prompted numerous investigations into identifying inflammatory gene variants that might predispose individuals to prostate cancer risk. (reviewed in [6]).

A 480 kilo base (kb) block of linkage disequilibrium (LD) at chromosomal position 4q27 (Figure 1), harbors two cytokine genes, *Interleukin (IL)-2* and *IL-21*. These genes encode proteins involved in numerous immune functions such as the activation and proliferation of immune cells including B-, T- and natural killer (NK) cells. IL-2, which is produced primarily by activated CD4+ effector T-cells, is a member of the common  $\gamma$ -chain cytokine family and appears to have pleiotropic effects in the immune system, acting as both a pro- and anti-inflammatory regulator [7]. Similarly, IL-2 has been described as contributing to both pro- and anti-tumor

\* Correspondence: vhayes@ccia.unsw.edu.au

<sup>1</sup>Cancer Genetics Group, Children's Cancer Institute Australia for Medical Research, Sydney Children's Hospital, High St, Randwick, NSW, Australia



immunity. In models of melanoma and renal cell carcinoma, administration of a high dose IL-2 based immunotherapy correlates with an elevated T regulatory (Treg) cell response associated with down regulation of tumor specific immunity [8]. Alternatively lower doses of IL-2 for treatment of common malignancies including prostate cancer contributes to an anti-tumor immune response via activation of tumor specific NK cells [9-11]. A balanced IL-2 cytokine production in the prostate microenvironment may thus contribute to prostate cancer susceptibility. To date, a single prostate cancer association study has investigated genetic variants within *IL-2* for prostate cancer risk and revealed a significant contribution of a synonymous *IL-2* exon 1 variant (rs2069763) to disease susceptibility [12].

IL-21 is the most recently described member of the common  $\gamma$ -chain cytokine family. Similarly to IL-2, IL-21 is expressed by activated CD4+ T-cells and has been described as having anti-tumor effects in mouse models for several different malignancies, including prostate cancer [13]. Experimental models have demonstrated the anti-tumor potential of IL-21, via expansion of

tumor specific CD8+ effector T cells and suppression of anti-inflammatory Treg cells [14]. IL-21 is involved in T-helper type 17 (Th17) effector cell function [15], which has been implicated in prostate cancer development [16] and more recently with progression to metastasis [17]. No studies have to date investigated the potential role of *IL21* variation in prostate cancer susceptibility.

In addition to *IL-2* and *IL-21*, the 480 kb region at 4q27 encompasses genes encoding testis nuclear RNA-binding protein (*TENR*) and a protein of unknown function, *KIAA1109*. The chromosomal region at position 4q27 has been highlighted as a potential risk locus in genome-wide association studies (GWAS) and candidate gene studies for several common inflammatory disorders including celiac disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis and both forms of inflammatory bowel disease (IBD), ulcerative colitis and Chron's disease [18-24]. Although replication studies have confirmed 4q27 as a risk locus for inflammatory disorders [22,24-29], tight linkage disequilibrium (LD), essentially

responsible for identification of the 4q27 region as a prostate cancer risk locus, in turn limits identification of the true casual variant.

The proposed link between the 4q27 locus and autoimmune disease susceptibility is suggestive of a functional role for this region in maintaining a balanced immune response. Under the proposed hypothesis that chronic inflammation may mediate prostate cancer development, further supported by casual observations of tentative association between the incidence of prostate cancer and several common immune disorders including ulcerative colitis [30], rheumatoid arthritis [31], Crohn disease [32] and asthma [33], we investigate a potential role for the 4q27 region in prostate cancer susceptibility. Six autoimmune associated variants and a single functional variant were genotyped using a large Australian-based case-control study of prostate cancer.

## Methods

### Study Population

The Risk Factors for Prostate Cancer (RFPC) study is a population-based case-control study of 825 cases and 734 controls from the Melbourne and Perth metropolitan areas of Australia, and defined in Additional file 1. The men of predominantly European descent (including 9 cases and 13 controls of Asian origin) were recruited between 1994 and 1998 and described in detail elsewhere [34]. Eligible cases were diagnosed with histopathologically confirmed prostate cancer via the State Cancer Registries and included irrespective of familial status. Cases were diagnosed before age 70 years with a Gleason Score >4. Tumor stage (stage I to IV) and grade (moderate: Gleason 5-7; high: Gleason 8-10) were obtained from histopathological reports. Controls were randomly selected from the State Electoral Rolls and frequency matched to the expected age distribution of cases. Information including age, family history of prostate cancer (in first-degree relatives), country of birth, and lifestyle were recorded during a face-to-face interview. Ethics approval for this study was obtained from The Cancer Council Victoria Human Research Ethics Committee, Australia (HREC0808).

### Variant Selection and Genotyping

Seven single nucleotide variants across the 4q27 locus were selected for analysis with prostate cancer risk. Six (rs13151961, rs13119723, rs17388568, rs3136534, rs6822844 and rs6840978) were chosen due to highly significant associations reported in previous studies for autoimmune disease susceptibility. These associations may reflect an as yet unknown biological effect of these variants. The *IL-2* promoter variant (rs2069762) was specifically selected based on previous functional reports [35,36].

The six variants rs13151961, rs13119723, rs17388568, rs3136534, rs6822844 and rs6840978 were genotyped using Applied Biosystem 7900HT TaqMan allelic discrimination method, with an average 11.5% random study replication. The *IL-2* promoter variant rs2069762, was genotyped on two platforms using the Sequenom MassArray using homogenous MassExtend (hME) and TaqMan allelic discrimination methods. Study replication was performed for the purpose of platform and chemistry assessment and quantification, as previously published [37].

### Statistical Analysis

Allele frequency estimates and tests of deviation from Hardy-Weinberg equilibrium (HWE) were carried out using standard procedures based on asymptotic likelihood theory [38]. Unconditional logistic regression analysis was used to test for independence between the variants and age (<55, 55-59, >60), country of birth (Australia, others) and family history of prostate cancer (affected first-degree relative and two or more first degree relatives affected). Case-control analyses were conducted using unconditional logistic regression and OR estimates and their 95% confidence intervals (CI) were derived under likelihood theory. We fitted dominant, recessive, co-dominant, and per allele models. Heterogeneity in the odds ratios by age and family history of prostate cancer in first-degree relatives (0 or at least one) was tested by including an interaction term in the logistic model. One polytomous logistic regression model was used to estimate odds ratios (OR) for stage I-II and stage III-IV tumors and another to estimate ORs for moderate-grade and high-grade tumors. In order to test for heterogeneity in the ORs by tumor stage or grade, the likelihood from these models was compared with that from polytomous logistic regression models with ORs constrained not to vary by tumour stage or grade. All statistical analyses were performed using Stata 10 (Stata Corporation). All tests were two-sided and a 5% level was used as the threshold for statistical significance.

### Results

Genotype calls were achieved for more than 99% of the study samples, with a 100% genotyping replication concordance using TaqMan allelic discrimination. Genotype distributions were consistent with HWE for cases and controls as well as cases and controls combined (all  $P > 0.19$ ). No significant association was observed between genotypes and tumor stage or grade, age of prostate cancer diagnosis, prostate-specific antigen (PSA) levels, or country of birth for any of the variants we assessed in this study.

Overall we found no significant association between the seven variants and prostate cancer risk (Additional

file 2). The per-allele ORs ranged from 0.92 (95% C.I. = 0.79-1.07) to 1.16 (95% C.I. = 1.00-1.35) and they were all not significantly different from 1 ( $P = 0.06$ ). The ORs were virtually unchanged after excluding the 22 men that were born in Asia. For rs3136534, the dominant model showed marginal evidence of association with risk: the OR for carriers of the rare allele versus carriers of two copies of the common allele was 1.23 (95% C.I. = 1.00-1.50,  $P$ -value = 0.046). Analysis by tumor stage, grade and age did not show any significant association. Analysis by family history of prostate cancer (Additional file 3) however showed evidence that the G allele for the intronic *KIAA1109* variant rs13119723, was significantly more frequent in men with a family history compared to those with no family history ( $P$ -value for interaction = 0.02). The per allele OR associated with this variant was significantly higher than 1 (2.37; 95% C.I. = 1.01-5.57) for men with a family history of prostate cancer.

Previous studies have reported a strong degree of LD within the 4q27 gene locus. Our results similarly support a high degree of linkage within this region (Figure 1).

## Discussion

Results using the RFPCS suggest that genetic variation at chromosomal region 4q27 is not associated with overall prostate cancer risk. At 0.05 level of significance under a dominant model the sample size of our study allows to detect with 80% power a minimum OR of 1.33 for the most common SNP (rs2069762) and 1.36 for the least common SNP (rs13151961). The corresponding minimum detectable ORs under a recessive model are 1.54 and 2.11. Analysis of men with a family history of the disease, however, indicates that this region may be a risk locus for familial prostate cancer.

The potential role of chronic inflammation in prostate cancer development, together with an observed association between the 4q27 region and susceptibility to autoimmune disease and in turn immune dysfunction, implicates the cytokine rich 4q27 region as a candidate prostate cancer risk locus. IL-2 and IL-21 are involved in regulating an immune response at multiple intervals, thus genetic variation likely to influence the function of these cytokines may have catastrophic effects to host immunity.

Although *IL-2* is well studied for association with autoimmune diseases, only a single study has investigated genetic association with risk for prostate cancer, implicating an indirect prostate cancer susceptibility marker [12], with no direct functional significance [39]. In our study we elected to screen the promoter variant rs2069762, shown to influence IL-2 production up to 3-fold [35,36] for a possible direct association. Although our results show no significant association for rs2069762, this is the first study to address the potential role of this variant in prostate cancer risk. The variant

rs3136534 in the *IL2* 3' untranslated region (UTR) however, displayed a marginally significant association with risk for prostate cancer.

The *IL-21* gene is still considered a relatively newly discovered cytokine, and thus few disease association studies have been reported. Candidate gene studies have identified single variants (not observed on GWAS) within *IL-21* to be associated with autoimmune diseases including SLE [40], type 1 diabetes [41] and atopic asthma [42]. The latter study identified a synonymous exon 3 variant (rs4833837), also reported to correlate with serum levels of immunoglobulin (Ig)E and IL-21 [42]. These results further implicate IL-21 in maintaining and regulating an immune response, although a high degree of LD within this gene region has hindered efforts to narrow the locus to its true causal variants. Despite suggestions that rs4833837 is associated with differential IL-21 activity, as yet no direct functional role for any *IL-21* variant has been reported. In this study we selected variants that were most significantly associated with autoimmune disease susceptibility and are the first, to our knowledge to investigate variants within the *IL-21* gene region for prostate cancer risk.

A family history of prostate cancer has long been accepted as a major contributor to an increased risk of developing the disease [2]. Identification of variants responsible for this inherent risk can be achieved by assessing variant frequency in cases with affected relatives. For the *KIAA1109* rs13119723 variant, we found an increased OR for men with a family history of prostate cancer. This result reflects a different genotype distribution for both cases and controls with a family history compared with cases and controls with no family history. However, we cannot exclude the possibility that the increased OR may be due to chance and to the relatively small number of men with a family history of prostate cancer in our study.

Although prostate cancer GWAS have thus far failed to implicate the 4q27 region as a candidate risk locus, the growing number of candidate gene regions already identified in these large-scale studies, highlights the complex and heterogeneous nature of prostate cancer. Thus, multiple, low to moderate risk alleles (not yet identified by GWAS) may still be implemented in the disease. It could therefore be argued that our pathway-linked gene approach to identify modest risk loci, in combination with large scale GWAS, may be appropriate to ensure complete coverage of potential prostate cancer risk factors.

## Conclusions

To establish whether the 4q27 cytokine rich region is a locus for familial prostate cancer risk as suggested in this study, the association needs to be replicated in independent studies that include a larger number of men with a

family history of the disease. In addition to harboring a gene of as yet unknown function, few functionally relevant variants within this region have been elucidated. Hence, a more comprehensive analysis of potentially functional variants within 4q27 may provide a more accurate approach for analysis of prostate cancer susceptibility.

**Additional file 1: Table S1.** Characteristics of participants in the Australian Risk Factors for Prostate Cancer Study  
Click here for file  
[<http://www.biomedcentral.com/content/supplementary/1471-2407-10-69-S1.DOC>]

**Additional file 2: Table S2.** Allele and genotype distributions for seven variants across chromosome 4q27 and prostate cancer risk  
Click here for file  
[<http://www.biomedcentral.com/content/supplementary/1471-2407-10-69-S2.DOC>]

**Additional file 3: Table S3.** Association between variants and prostate cancer risk by family history of prostate cancer  
Click here for file  
[<http://www.biomedcentral.com/content/supplementary/1471-2407-10-69-S3.DOC>]

#### Acknowledgements

We are grateful to the study participants, as well as the many urologists, nurses and histopathologists who kindly facilitated in the recruitment and collection of patient information and pathology reports. This study was supported by grants from the National Health and Medical Research Council (#396407, #504700, and #504702), Cancer Institute of New South Wales (VMH is a Fellow and EAT a PhD Scholar), and Australian Rotary Health Research (EAT is a PhD Scholar). Infrastructure support was provided from the Children's Cancer Institute Australia for Medical Research, the Cancer Council Victoria and from the Australian Cancer Research Foundation Unit for the Molecular Genetics of Cancer (located at the Garvan Institute for Medical Research, for Sequenom generated data).

#### Author details

<sup>1</sup>Cancer Genetics Group, Children's Cancer Institute Australia for Medical Research, Sydney Children's Hospital, High St, Randwick, NSW, Australia. <sup>2</sup>Faculty of Medicine, University of New South Wales, Randwick, NSW Australia. <sup>3</sup>Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Vic, Australia. <sup>4</sup>Department of Pathology, University of Melbourne, Melbourne, Vic, Australia. <sup>5</sup>Centre for Molecular, Environmental, Genetic, and Analytical Epidemiology, University of Melbourne, Melbourne, Vic, Australia.

#### Authors' contributions

EAT participated in the design of the study, performed all genotyping and drafted the manuscript. The data contained within will contribute partial fulfillment of the requirements for the Degree of Doctor of Philosophy for EAT. MCS, DRE, JLH and GGG were responsible for collection and maintaining the epidemiological resource. HNH and GS performed statistical analysis and helped draft the manuscript. VMH facilitated the study design, analysis and drafted manuscript. All authors read and approved the final manuscript.

#### Competing interests

The authors declare that they have no competing interests.

Received: 11 November 2009

Accepted: 25 February 2010 Published: 25 February 2010

#### References

1. Baade PD, Youlten DR, Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. *Mol Nutr Food Res* 2009, **53**(2):171-184.

2. Fleshner NE, Lawrentschuk N: Risk of developing prostate cancer in the future: overview of prognostic biomarkers. *Urology* 2009, **73**(5 Suppl): S21-27.
3. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C: Inflammation and prostate cancer. *Future Oncol* 2008, **4**(5):637-645.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. *Nature Reviews Cancer* 2007, **7**:256-269.
5. Sandhu JS: Prostate cancer and chronic prostatitis. *Curr Urol Rep* 2008, **9**(4):328-332.
6. Sun J, Turner A, Xu J, Grönberg H, Isaacs W: Genetic variability in inflammation pathways and prostate cancer risk. *Urological Oncology* 2007, **25**(3):250-259.
7. Hoyer KK, Dooms H, Barron L, Abbas AK: Interleukin-2 in the development and control of inflammatory disease. *Immunol Rev* 2008, **226**:19-28.
8. Vliet van der HJ, Koon HB, Yue SC, Uzunpamuk B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA: Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. *Clin Cancer Res* 2007, **13**(7):2100-2108.
9. Brill TH, Kubler HR, Pohla H, Buchner A, Fend F, Schuster T, von Randenborgh H, Paul R, Kummer T, Plank C, et al: Therapeutic Vaccination with an IL-2-IFN $\gamma$ -secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer - a Phase I/II Trial. *Hum Gene Ther* 2009.
10. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR, Murphy WJ: Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. *Biol Blood Marrow Transplant* 2008, **14**(10):1088-1099.
11. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL: Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. *Clin Cancer Res* 2008, **14**(16):5284-5291.
12. Wu H-C, Chang C-H, Wan L, Wu C-I, Tsai F-J, Chen W-C: IL-2 gene C/T polymorphism is associated with prostate cancer. *Journal of Clinical Laboratory Analysis* 2006, **20**(6):245-249.
13. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL: IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. *J Immunol* 2005, **175**(4):2167-2173.
14. Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL: Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. *Mol Ther* 2009, **17**(2):380-388.
15. Huber M, Brustle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von Low E, Lohoff M: IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. *Proc Natl Acad Sci USA* 2008, **105**(52):20846-20851.
16. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. *Clin Cancer Res* 2008, **14**(11):3254-3261.
17. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G: Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. *Int J Cancer* 2009, **125**(6):1372-1379.
18. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007, **447**(7145):661-678.
19. Festen EA, Goyette P, Scott R, Annesse V, Zhernakova A, Lian J, Lefebvre C, Brant SR, Cho JH, Silverberg MS, et al: Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. *Gut* 2009, **58**(6):799-804.
20. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, et al: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet* 2008, **4**(3):e1000041.
21. van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, Wapenaar MC, Barnardo MC, Bethel G, Holmes GK, et al: A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. *Nat Genet* 2007, **39**(7):827-829.
22. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B, Franke L, Posthumus MD, van Heel DA, Steege van der G, et al:

- Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. *Am J Hum Genet* 2007, **81**(6):1284-1288.
23. Fedetz M, Ndagire D, Fernandez O, Leyva L, Guerrero M, Arnal C, Lucas M, Izquierdo G, Delgado C, Alcina A, et al: **Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population.** *Tissue Antigens* 2009, **74**(3):244-247.
  24. Marquez A, Orozco G, Martinez A, Palomino-Morales R, Fernandez-Arquero M, Mendoza JL, Taxonera C, Diaz-Rubio M, Gomez-Garcia M, Nieto A, et al: **Novel Association of the Interleukin 2-Interleukin 21 Region With Inflammatory Bowel Disease.** *Am J Gastroenterol* 2009.
  25. Adamovic S, Amundsen SS, Lie BA, Gudjonsdottir AH, Ascher H, Ek J, van Heel DA, Nilsson S, Sollid LM, Torinsson Naluai A: **Association study of IL2/IL21 and FcγRIIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families.** *Genes Immun* 2008, **9**(4):364-367.
  26. Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, Allen JE, Downes K, Barrett JC, Healy BC, Mychaleckyj JC, et al: **Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci.** *Nat Genet* 2008, **40**(12):1399-1401.
  27. Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, et al: **Novel Genetic Risk Markers for Ulcerative Colitis in the IL2/IL21 Region Are in Epistasis With IL23R and Suggest a Common Genetic Background for Ulcerative Colitis and Celiac Disease.** *Am J Gastroenterol* 2009.
  28. Romanos J, Barisani D, Trynka G, Zhernakova A, Bardella MT, Wijmenga C: **Six new coeliac disease loci replicated in an Italian population confirm association with coeliac disease.** *J Med Genet* 2009, **46**(1):60-63.
  29. Garner CP, Murray JA, Ding YC, Tien Z, van Heel DA, Neuhausen SL: **Replication of Celiac Disease UK Genome-Wide Association Study Results in a US Population.** *Hum Mol Genet* 2009.
  30. Hemminki K, Li X, Sundquist J, Sundquist K: **Cancer risks in ulcerative colitis patients.** *Int J Cancer* 2008, **123**(6):1417-1421.
  31. Hemminki K, Li X, Sundquist K, Sundquist J: **Cancer risk in hospitalized rheumatoid arthritis patients.** *Rheumatology (Oxford)* 2008, **47**(5):698-701.
  32. Hemminki K, Li X, Sundquist J, Sundquist K: **Cancer risks in Crohn disease patients.** *Ann Oncol* 2009, **20**(3):574-580.
  33. Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K: **Cancer risk in hospitalised asthma patients.** *Br J Cancer* 2009, **100**(5):829-833.
  34. Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, et al: **ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.** *J Natl Cancer Inst* 2003, **95**(11):818-824.
  35. Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez O, Alcina A: **Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression.** *J Neuroimmunol* 2004, **148**(1-2):212-217.
  36. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ: **Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes.** *Transplantation* 2001, **72**(8):1444-1450.
  37. Tindall EA, Speight G, Petersen DC, Padilla EJ, Hayes VM: **Novel Plexor SNP genotyping technology: comparisons with TaqMan and homogenous MassEXTEND MALDI-TOF mass spectrometry.** *Hum Mutat* 2007, **28**(9):922-927.
  38. Sham PC: **Statistics in human genetics. Applications of statistics.** London: Arnold 1998.
  39. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE, Hutchinson IV, Hajeer AH: **Two novel biallelic polymorphisms in the IL-2 gene.** *Eur J Immunogenet* 1998, **25**(6):419-420.
  40. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, et al: **Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus.** *Ann Rheum Dis* 2008, **67**(4):458-461.
  41. Asano K, Ikegami H, Fujisawa T, Nishino M, Nojima K, Kawabata Y, Noso S, Hiromine Y, Fukai A, Ogihara T: **Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes.** *Hum Immunol* 2007, **68**(5):384-391.
  42. Chatterjee R, Batra J, Ghosh B: **A common exonic variant of interleukin21 confers susceptibility to atopic asthma.** *Int Arch Allergy Immunol* 2009, **148**(2):137-146.

#### Pre-publication history

The pre-publication history for this paper can be accessed here:<http://www.biomedcentral.com/1471-2407/10/69/prepub>

doi:10.1186/1471-2407-10-69

**Cite this article as:** Tindall et al.: The 4q27 locus and prostate cancer risk. *BMC Cancer* 2010 **10**:69.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

